CTIS2024-512508-21-00进行中（未招募）1 期
carnitine as an adjunct treatment for septic shock patients with acute kidney injury: a multicentre, randomized, 2-parallel group, superiority trial
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 272
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •The emergency inclusion procedure was correctly applied according to French law (signature of consent form by a patient-designated trusted person or a family member, or a medical decision to proceed with patient inclusion if the latter two persons are unavailable) ---- OR ---- signature of the consent form by the patient, •The patient must be insured or beneficiary of a health insurance plan, •The patient is at least 18 years old, •The patient was admitted to an intensive care unit (participating in the study) for sepsis or septic shock and presented with acute renal failure requiring, at some point, the use of extra-renal purification, The patient has sepsis or septic shock according to international criteria SEPSIS 3 (Singer et al, The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) ; JAMA. 2016), •The patient has acute renal insufficiency with an KDIGO score of 3, •The patient has started continuous renal replacement therapy (CRRT) or intermittent renal replacement therapy (IRRT) within the past 72 hours, or will start RRT (CRRT or IRRT) within the next 72 hours.
排除标准
- •The patient is participating in, or has participated in over the past three months, another interventional study that may interfere with the results or conclusions of this study, •Septic shock without associated AKI, •Patients with a known allergy to L-Carnitine or other component of levocarnil oral solution or for injection, •Pre-existing chronic disease requiring dialysis, •The patient has stage 4 CKD with baseline DFG (CDK) if known <30 ml, •History of seizures or epilepsy, •Chronic bowel disease or history of chronic diarrhoea, •Under treatment with sodium valproate, •The patient is in an exclusion period determined by a previous study, •The patient is under judicial protection, or is an adult under guardianship, •The patient is pregnant, parturient or breastfeeding, •The patient is susceptible to procreate and does not use methods of effective contraception (contraceptive hormonal ring, surgical contraception, contraceptive implant, contraceptive pill, male or female sheaths, skin patch, intrauterine contraceptive device), •If the patient is unable to sign a consent form: the patient-designated trusted person or family member refuses to sign the consent form, •If the patient is unable to sign a consent form: It is impossible to correctly inform the patient-designated trusted person or family member, •The patient is able/apt to sign a consent form, but refuses to do so, •The patient is able/apt to sign a consent form, but cannot be correctly informed
研究者
相似试验
进行中（未招募）
1 期
étude d'un traitement complémentaire de L-carnitine chez des patients en choc septique avec une défaillance rénale aiguepatients devant bénéficier d'un traitement pour choc septique, accompagné d'insuffisance rénale aigüeMedDRA version: 20.0Level: LLTClassification code 10040580Term: Shock septicSystem Organ Class: 100000019974EUCTR2016-001977-34-FRCHU de Nîmes272
终止
3 期
L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney InjurySevere SepsisShock, SepticAcute Kidney InjuryNCT02664753Centre Hospitalier Universitaire de Nīmes254
已完成
1 期
Acetyl-L-Carnitine in the Treatment of Septic ShockSeptic ShockNCT00592488Vanderbilt University13
终止
1 期
L-Carnitine Administration in Early SepsisSeptic ShockNCT01193777Wake Forest University Health Sciences31
招募中
不适用
Ketanest in septic shock.Patients in need for intubation in early septic shock.NL-OMON2880920